By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Saltire Court, 4th Floor
20 Castle Terrace
Edinburgh  Lothian  EH1 2EN  United Kingdom
Phone: Fax:


Start Up

Company News
ASCO2016: NuCana Acelarin Achieves High Clinical Activity And Durable Disease Control In Patients With Recurrent Ovarian Cancer 6/6/2016 3:54:50 PM
NuCana Presents Exciting Data On Novel Anticancer Agent, NUC-3373, At The AACR-NCI-EORTC Conference In Boston 11/9/2015 7:38:06 AM
Internationally Renowned Medicinal Chemist Professor Chris Mcguigan Appointed As NuCana’s Chief Scientific Officer 7/1/2015 2:56:04 PM
NuCana Appoints Martin J Birkhofer, M.D. As Chief Medical Officer 6/22/2015 8:39:27 AM
NuCana Release: Ground-Breaking Final Results Of The First In Human Phase I/II Study With Acelarin In Advanced Solid Tumours 6/1/2015 2:16:59 PM
NuCana Release: Acelarin Achieves Very High Disease Control Rates In Patients With Advanced Gynaecological Cancers In A Phase I/II Setting 6/1/2015 2:12:58 PM
NuCana Appoints Dr. Paolo Paoletti To Its Board Of Directors 12/1/2014 7:06:24 AM
NuCana Hauls In $57 Million 4/11/2014 6:43:25 AM
NuCana Names Royal Society Award Winner As Consultant 10/5/2006 11:59:31 AM
NuCana Signs Exclusive Agreement With Cardiff Protides To Acquire Novel Cancer Agents And Technology 9/14/2006 10:00:00 AM